Furthermore, Lopergolo et al. investigated whether the combination therapy with the RET-targeting tyrosine kinase inhibitor sunitinib and cisplatin can enhance apoptosis in MTC cell lines harboring the RET M918T oncogene and xenograft mouse model (95). Here, RET is linked to medullary thyroid gland carcinoma.